New publication on glyco-CARTs for the treatment of solid cancers
A collaboration with U. Copenhagen and UPenn
GO Therapeutics CSO review on site-specific O-glycans in human tissue formation, O-glycan occupancy, and contributions from individual GalNAc-Ts
Professor Hans Wandall review published in Nature
Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology
Collaboration to Accelerate Next-Generation Cancer Treatment
Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin
GO Therapeutics Scientific Co-Founder & Chief Scientific Officer Hans Wandall, M.D., Ph.D. co-authors article published in British Journal of Cancer.
GO Therapeutics Enters into a License Agreement with Roche for New Glycotargeting Bispecific Cancer Treatment
Under the terms of the agreement, GO will grant Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target to develop and commercialize a new glycotargeting bispecific antibody.
Salubris Pharmaceuticals Invests $5 Million in GO Therapeutics
Strategic investment to help accelerate antibody development programs against novel solid tumor targets.